Neurocrine biosciences receives orphan drug designation for valbenazine as a treatment for chorea associated with huntington disease

San diego, may 12, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that it has received orphan drug designation from the u.s. food and drug administration (fda) for valbenazine as a treatment for huntington disease (hd). the treatment of chorea associated with hd is within the scope of this orphan drug designation.
NBIX Ratings Summary
NBIX Quant Ranking